Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA

NCT06569225 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma Resectable

Interventions

DRUG: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig

Sponsor

University Health Network, Toronto

Collaborators

[object Object]
[object Object]